Literature DB >> 16389538

Anti-inflammatory effect of an Escherichia coli extract in a mouse model of lipopolysaccharide-induced cystitis.

Seung-Ju Lee1, Sae Woong Kim, Yong-Hyun Cho, Moon Soo Yoon.   

Abstract

The bacterial extract, Uro-Vaxom, which consists of immunostimulating components derived from 18 Escherichia coli strains, was used for the prophylaxis of recurrent cystitis. To evaluate the anti-inflammatory effect of E. coli extract, we measured the cytokine levels of bladder tissue after oral administration and analyzed bladder inflammation by histopathologic examination in a model of lipopolysaccharide (LPS)-induced cystitis in mice. After oral administering the E. coli extract for 10 days, the cytokine [interleukin-6 (IL-6), IL-10, monocyte chemoattractant protein-1, interferon-gamma (IFN-gamma), tumor necrosis factor-alpha, IL-12p70] levels present in the bladder of female Balb/C mice were determined using a cytometric bead array. The bladder macrophage inflammatory protein-2 level was also measured using a sandwich enzyme immunoassay. After immunization with the E. coli extract, E. coli LPS was instilled into the bladders intravesically. Twenty-four hours later, the mice were sacrificed and the level of bladder inflammation was quantified using the bladder inflammatory index (BII). Significant changes in the bladder IL-6 and IFN-gamma levels were observed after the E. coli extract treatment. Secretions of the other cytokines were not stimulated by the E. coli extract. The bladder instilled with LPS had high inflammation scores for edema, leukocyte infiltration, and hemorrhage in the saline treated control mice. In contrast, the E. coli extract treated mice exhibited mild inflammation of their bladders with a significant reduction in the BII scores compared with the controls. These findings might explain the anti-inflammatory effect of the E. coli extract demonstrated in clinical studies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16389538     DOI: 10.1007/s00345-005-0046-y

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  24 in total

1.  Biological activity of bacterial surface components: bacterial extracts and defined bacterial cell wall components as immunomodulators.

Authors:  W G Bessler; B Kleine; C Martinez Alonso; L Biesert; M Strecker; K H Wiesmüller; J Metzger; G Jung
Journal:  Lung       Date:  1990       Impact factor: 2.584

2.  Simultaneous measurement of six cytokines in a single sample of human tears using microparticle-based flow cytometry: allergics vs. non-allergics.

Authors:  E B Cook; J L Stahl; L Lowe; R Chen; E Morgan; J Wilson; R Varro; A Chan; F M Graziano; N P Barney
Journal:  J Immunol Methods       Date:  2001-08-01       Impact factor: 2.303

Review 3.  Management of urinary tract infections in adults.

Authors:  W E Stamm; T M Hooton
Journal:  N Engl J Med       Date:  1993-10-28       Impact factor: 91.245

Review 4.  Recurrent urinary tract infection in women.

Authors:  T M Hooton
Journal:  Int J Antimicrob Agents       Date:  2001-04       Impact factor: 5.283

5.  Histological and neurotrophic changes triggered by varying models of bladder inflammation.

Authors:  M C Dupont; J M Spitsbergen; K B Kim; J B Tuttle; W D Steers
Journal:  J Urol       Date:  2001-09       Impact factor: 7.450

6.  Oral immunotherapy in paraplegic patients with chronic urinary tract infections: a double-blind, placebo-controlled trial.

Authors:  H J Hachen
Journal:  J Urol       Date:  1990-04       Impact factor: 7.450

7.  Metabolic and functional stimulation of lymphocytes and macrophages by an Escherichia coli extract (OM-89): in vitro studies.

Authors:  T Van Pham; B Kreis; S Corradin-Betz; J Bauer; J Mauël
Journal:  J Biol Response Mod       Date:  1990-04

8.  Biological activity of bacterial surface components. Immunogenicity and immunomodulatory properties of a bacterial extract from Escherichia coli.

Authors:  W G Bessler; P Beck; U Konetznick; M Loleit; E Sedelmeier; P Hoffmann; M Strecker; S Stöcklin
Journal:  Arzneimittelforschung       Date:  1991-03

9.  Recurring urinary tract infection: incidence and risk factors.

Authors:  B Foxman
Journal:  Am J Public Health       Date:  1990-03       Impact factor: 9.308

10.  Uro-Vaxom and the management of recurrent urinary tract infection in adults: a randomized multicenter double-blind trial.

Authors:  P Magasi; J Pánovics; A Illés; M Nagy
Journal:  Eur Urol       Date:  1994       Impact factor: 20.096

View more
  8 in total

Review 1.  Host-pathogen checkpoints and population bottlenecks in persistent and intracellular uropathogenic Escherichia coli bladder infection.

Authors:  Thomas J Hannan; Makrina Totsika; Kylie J Mansfield; Kate H Moore; Mark A Schembri; Scott J Hultgren
Journal:  FEMS Microbiol Rev       Date:  2012-05       Impact factor: 16.408

Review 2.  Modulation of connexin signaling by bacterial pathogens and their toxins.

Authors:  Liesbeth Ceelen; Freddy Haesebrouck; Tamara Vanhaecke; Vera Rogiers; Mathieu Vinken
Journal:  Cell Mol Life Sci       Date:  2011-06-09       Impact factor: 9.261

3.  Immunostimulation in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): a one-year prospective, double-blind, placebo-controlled study.

Authors:  Florian M E Wagenlehner; Stefania Ballarini; Kurt G Naber
Journal:  World J Urol       Date:  2014-01-31       Impact factor: 4.226

Review 4.  Drug and Vaccine Development for the Treatment and Prevention of Urinary Tract Infections.

Authors:  Valerie P O'Brien; Thomas J Hannan; Hailyn V Nielsen; Scott J Hultgren
Journal:  Microbiol Spectr       Date:  2016-02

Review 5.  Nitric oxide as a target of complementary and alternative medicines to prevent and treat inflammation and cancer.

Authors:  Lorne J Hofseth
Journal:  Cancer Lett       Date:  2008-04-25       Impact factor: 8.679

6.  Prevention of anti-microbial peptide LL-37-induced apoptosis and ATP release in the urinary bladder by a modified glycosaminoglycan.

Authors:  Won Yong Lee; Justin R Savage; Jianxing Zhang; Wanjian Jia; Siam Oottamasathien; Glenn D Prestwich
Journal:  PLoS One       Date:  2013-10-30       Impact factor: 3.240

Review 7.  How does Helicobacter pylori cause gastric cancer through connexins: An opinion review.

Authors:  Huan Li; Can-Xia Xu; Ren-Jie Gong; Jing-Shu Chi; Peng Liu; Xiao-Ming Liu
Journal:  World J Gastroenterol       Date:  2019-09-21       Impact factor: 5.742

8.  Effect of a bioactive product SEL001 from Lactobacillus sakei probio65 on gut microbiota and its anti-colitis effects in a TNBS-induced colitis mouse model.

Authors:  Irfan A Rather; Vivek K Bajpai; Lew L Ching; Rajib Majumder; Gyeong-Jun Nam; Nagaraju Indugu; Prashant Singh; Sanjay Kumar; Nahid H Hajrah; Jamal S M Sabir; Majid Rasool Kamli; Yong-Ha Park
Journal:  Saudi J Biol Sci       Date:  2019-09-04       Impact factor: 4.219

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.